Veristat launched InStat, an automated biostatistics platform designed to cut clinical trial readout timelines from weeks to days. The CRO said the system produces submission-ready tables, listings and figures in five days or less by translating biostatisticians’ descriptions into precise specifications and running them through validated statistical engines. Veristat’s first sponsor, Clene Nanomedicine, used InStat for NfL biomarker analyses tied to its accelerated approval pathway under Subpart H for CNM-Au8, where speed in data processing can be a meaningful lever. The launch positions workflow automation and rapid analytics as a competitive differentiator among CROs, especially as sponsors push for earlier regulatory decision-making and tighter development cycles.